Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects

Sunshine Lake Pharma

Status and phase

Completed

Phase 1

Conditions

Diabetic Nephropathy

Treatments

Drug: HEC73077 placebo tablets

Drug: HEC73077 tablets

Study type

Interventional

Funder types

Industry

Identifiers

HEC73077-P-01

Details and patient eligibility

About

The Safety, Tolerability Pharmacokinetic and Food Effect Study of HEC73077 in Healthy Subjects

Enrollment

138 patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions.
Be able to complete the study according to the trail protocol.
Subjects (including partners) have no pregnancy plan within 6 months after the last dose of study drug and voluntarily take effective contraceptive measures.
subjects and must be 18 to 45 years of age inclusive.
Body weight ≥ 45 kg(for female) or ≥ 50 kg(for male) and body mass index（BMI）between 18 and 28 kg / m^2, inclusive, at screening.
There was no clinically significant medical history of respiratory, circulatory, digestive, urinary, blood, endocrine, nervous system diseases and metabolic abnormalities at screening.
Subjects, who are healthy, as having no clinically significant abnormalities in vital signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead electrocardiogram (ECG).

Exclusion criteria

Use of >5 cigarettes per day during the past 3 months.
Known history of allergy to study drugs，or allergies constitution ( multiple drug and food allergies).
History of alcoholism or drink regularly within 3 months prior to the study (defined as Alcohol consumption of > 14 units/week).
Positive results from urine drug screen test.
Donation or loss of blood over 450 mL within 3 months prior to screening.
Subjects suffering from gastrointestinal diseases that can interfere with absorption or metabolism of drugs within 6 months before screening.
Use of any prescription or non-prescription medications within 14 days prior to initial dosing
Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing.
Subjects who participated in another clinical trial within 3 months prior to initial dosing.
Female subjects were lactating or had positive serum pregnancy results during the screening or testing period.
Subjects deemed unsuitable by the investigator for any other reason.